世界の乳房生検装置市場の収益は、2023 年に 16 億ドル相当と推定され、2028 年までに 26 億ドルに達する見込みで、2023 年から 2028 年にかけて 10.0% の CAGR で成長します。新しい調査研究は業界の動向から構成されています。市場の分析。新しい調査研究は、業界のトレンド、価格分析、特許分析、カンファレンスとウェビナーの資料、主要な利害関係者、市場の購買行動で構成されています。
								
						目次
						
	TABLE OF CONTENT
	1 Introduction
	
	1.1 Objectives of the Study
	1.2 Market Definition
	1.2.1 Key Inclusions & Exclusions
	1.3 Research Scope
	1.3.1 Segments Covered
	1.3.2 Geographic Scope
	1.3.3 Years Considered For the Study
	1.4 Currency Used For the Study
	1.5 Major Market Stakeholders
	1.6 Summary of Changes
	1.6.1 Recession Impact
	2 Research Methodology
	
	2.1 Research Data Sources
	2.1.1 Secondary Data
	2.1.2 Primary Data
	2.2 Market Size Estimation Methodology
	2.3 Market Share Estimation Methodology
	2.4 Market Break Down and Data Triangulation
	2.5 Research Assumptions
	2.6 Research Limitations
	2.6.1 Scope Related Limitations
	2.6.2 Methodology Related Limitations
	2.7 Recession Impact Assessment Approach
	2.8 Risk Assessment
	3 Executive Summary
	4 Premium Insights
	5 Market Overview
	
	5.1 Introduction
	5.2 Market Dynamics
	5.2.1 Major Drivers
	5.2.2 Key Restraints
	5.2.3 Key Growth Opportunities
	5.2.4 Industry-Specific Challenges
	5.3 Regulatory Landscape
	5.3.1 Regulatory Bodies, Government Agencies and Other Organizations
	5.3.2 Regulatory Analysis
	5.4 Value Chain Analysis
	5.5 Supply Chain Analysis
	5.6 Ecosystem Market Map
	5.7 Technology Analysis
	5.8 Trade Data Analysis
	5.9 Patent Analysis
	5.10 Porter’s Five Force Analysis
	5.11 Pricing Analysis
	5.11.1 Average Selling Price of Key Players By Product
	5.11.2 Average Selling Price Trends
	5.12 Case Study Analysis
	5.13 Key Conferences and Events In 2022-23
	5.14 Key Stakeholders and Buying Criteria
	5.14.1 Key Stakeholders and Buying Criteria
	5.14.2 Buying Criteria
	6 Breast Biopsy Devices Market, By Type (USD Million; 2021—2028)*
	
	6.1 Introduction
	6.2 Biopsy Needles
	6.3 Guidance Systems
	6.4 Biopsy Tables
	6.5 Localization Wires
	6.6 Assay Kits
	6.7 Liquid Biopsy Instruments
	6.8 Other Devices
	7 Breast Biopsy Devices Market, By Procedure (USD Million; 2021—2028)*
	
	7.1 Introduction
	7.2 Needle Breast Biopsy
	7.2.1 Core-Needle Biopsy (CNB)
	7.2.2 Fine-Needle Aspiration Biopsy (FNAB)
	7.2.3 Vacuum-Assisted Biopsy (VAB)
	7.3 Open Surgical Breast Biopsy
	7.3.1 Excisional
	7.3.2 Incisional
	7.4 Liquid Breast Biopsy
	7.4.1 Circulating Tumor Cells (CTC)
	7.4.2 Circulating Tumor CNA (CtDNA)
	7.4.2 Other Biomarkers
	8 Breast Biopsy Devices Market, By Technique (USD Million; 2021—2028)*
	
	8.1 Introduction
	8.2 Image Guided Biopsy
	8.2.1 Mammography-Guided/Stereotactic
	8.2.2 Ultrasound-Guided
	8.2.3 MRI-Guided
	8.2.3 Other Image-Guided Techniques
	8.3 Liquid Biopsy
	8.3.1 NGS Based Biopsy
	8.3.2 PCR Based Biopsy
	8.3.3 Microarray Based Biopsy
	9 Breast Biopsy Devices Market, By Application (USD Million; 2021—2028)*
	
	9.1 Introduction
	9.2 Early Cancer Screening
	9.3 therapy Selection
	9.4 Treatment Monitoring
	9.5 Recurrence Monitoring
	10 Breast Biopsy Devices Market, By End-User (USD Million; 2021—2028)*
	
	10.1 Introduction
	10.2 Hospitals & Surgical Centers
	10.3 Breast Care Centers
	10.4 Imaging Clinics & Diagnostic Centers
	11 Breast Biopsy Devices Market, By Region (USD Million; 2021—2028)*
	
	11.1 North America
	11.1.1 Recession Impact
	11.1.2 US
	11.1.3 Canada
	11.2 Europe
	11.2.1 Recession Impact
	11.2.2 Germany
	11.2.3 UK
	11.2.4 France
	11.2.5 Italy
	11.2.6 Spain
	11.2.7 Rest of Europe
	11.3 Asia-Pacific
	11.3.1 Recession Impact
	11.3.2 Japan
	11.3.3 China
	11.3.4 India
	11.3.5 South Korea
	11.3.6 Australia
	11.3.7 Rest of Asia-Pacific
	11.4 Latin America
	11.4.1 Recession Impact
	11.4.2 Brazil
	11.4.3 Mexico
	11.4.4 Rest of Latin America
	11.5 Middle East and Africa
	11.5.1 Recession Impact
	12 Competitive Landscape
	
	12.1 Overview
	12.2 Revenue Share Analysis of Key Players (2022)
	12.3 Market Share Analysis For Top 5 Global Players (In Terms of %Revenue, In 2022)
	12.4 Company Footprint Analysis
	12.5 Competitive Benchmarking
	12.6 Competitive Situation and Trends (2021-2023)
	12.6.1 Product Launches and Approvals
	12.6.2 Deals
	12.7 Company Evaluation Quadrant
	12.7.1 Pervasive Players
	12.7.2 Emerging Leaders
	12.7.3 Participants
	12.7.4 Stars
	12.8 SME/Start-Up Evaluation Quadrant
	12.8.1 Progressive Companies
	12.8.2 Responsive Companies
	12.8.3 Dynamic Companies
	12.8.4 Starting Blocks
	12.9 Key Players Strategies-Right To Win
	13 Company Profiles**
	
	13.1 Major Players
	13.1.1 Hologic Inc.
	13.1.2 Danaher Corporation
	13.1.3 Becton, Dickinson and Company
	13.1.4 Argon Medical Devices
	13.1.5 Guardant Health, Inc.
	13.1.6 Merit Medical Systems
	13.1.7 Menarini-Silicon Biosystems
	13.1.8 NeoGenomics
	13.1.9 Sysmex Inostics
	13.1.10 Sterylab S.R.L.
	13.1.11 Biocept, Inc.
	13.1.12 Bio-Rad Laboratories, Inc.
	13.1.13 F. Hoffmann-La Roche Ltd
	13.1.14 Qiagen
	13.1.15 Exact Sciences Corporation
	13.2 Other Players
	13.2.1 Thermo Fisher Scientific
	13.2.2 Cardiff Oncology Inc.
	13.2.3 Myriad Genetics, Inc.
	13.2.4 Illumina, Inc
	13.2.5 Fluxion Biosciences, Inc.
	13.2.6 Fujifilm Holdings Corporation
	13.2.7 Inrad, Inc.
	13.2.8 IZI Medical Products
	13.2.9 Remington Medical Inc.
	13.2.10 CP Medical
	14 Appendix
	
	14.1 Discussion Guide
	14.2 Knowledge Store: Marketsandmarkets’ Subscription Portal
	14.3 Available Customizations
	14.4 Related Reports
	14.5 Author Details